Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Daniela Gioia"'
Autor:
Enrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, Bernardino Allione, Emanuele Angelucci, Marco Bruzzone, Tullio Calzamiglia, Marina Cavaliere, Maurizio Cavalleri, Daniela Cilloni, Marino Clavio, Elena Crisà, Anna Da Col, Paolo Danise, Federica Pilo, Dario Ferrero, Carlo Finelli, Daniela Gioia, Roberto Massimo Lemoli, Elisa Masiera, Emanuela Messa, Maurizio Miglino, Pellegrino Musto, Esther Natalie Oliva, Antonella Poloni, Flavia Salvi, Alessandro Sanna, Marco Scudeletti, Rodolfo Tassara, Valeria Santini
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7567-7576 (2019)
Abstract Background Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed
Externí odkaz:
https://doaj.org/article/138e7105345a42ddac1dc39908b0c2b5
Autor:
Emanuela Messa, Daniela Gioia, Elisa Masiera, Anna Castiglione, Manuela Ceccarelli, Flavia Salvi, Paolo Danise, Alessandro Sanna, Bernardino Allione, Enrico Balleari, Antonella Poloni, Giovanni Cametti, Dario Ferrero, Rodolfo Tassara, Carlo Finelli, Margherita Bonferroni, Pellegrino Musto, Giuseppe Saglio, Alessandro Levis, Valeria Santini
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/49fd98bf53e04381b570812f4522d35e
Autor:
Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, Valerio Zoli, Benedetta Puccini, Andrea Evangelista, Luca Arcaini, Leonardo Flenghi, Carlo Visco, Michael Mian, Alice Di Rocco, Claudia Peracchio, Manuel Gotti, Maria Chiara Tisi, Francesca Palombi, Samantha Pozzi, Daniela Gioia, Piera Viero, Maurizio Martelli
Publikováno v:
Hematological Oncology. 40:609-616
Salvage immunochemotherapy and transplant consolidation is the standard treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We tested a combination of Obinutuzumab and DHAP for treating R/R DLBCL. The primary end point w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8712f0929a08832d12510bbc132946
https://doi.org/10.1002/hon.3028
https://doi.org/10.1002/hon.3028
Autor:
Maurizio Miglino, Paolo Danise, Bernardino Allione, Federica Pilo, Valeria Santini, Antonella Poloni, Elisa Masiera, Daniela Cilloni, Enrico Balleari, Dario Ferrero, Pellegrino Musto, Marino Clavio, Emanuele Angelucci, Flavia Salvi, Anna Da Col, Emanuela Messa, Esther Oliva, Marco Bruzzone, Daniela Gioia, Rodolfo Tassara, Carlo Finelli, Marina Cavaliere, Chiara Salvetti, M. Cavalleri, Tullio Calzamiglia, Rosa Filiberti, Elena Crisà, Marco Scudeletti, Roberto M. Lemoli, Alessandro Sanna
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7567-7576 (2019)
Cancer Medicine
Cancer Medicine
Background Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f58d867c4ada296bee9851a8c5b44c3
https://doaj.org/article/138e7105345a42ddac1dc39908b0c2b5
https://doaj.org/article/138e7105345a42ddac1dc39908b0c2b5
Autor:
Alessandro Re, Luca Nassi, Armando Santoro, Daniela Gioia, Vittorio Ruggero Zilioli, Paola Franzone, Alessandro Pulsoni, Pier Luigi Zinzani, Luigi Rigacci, Monica Tani, Francesco Zaja, Mario Levis, Gabriele Simontacchi, Umberto Ricardi, Manuela Zanni, Antonio Nardella, Vincenzo Pavone, Michela Buglione, Andrea Riccardo Filippi, Delia Rota-Scalabrini, Manuel Gotti, Barbara Botto, Giovanni Frezza, Elisabetta Abruzzese, Gian Mauro Sacchetti, Lavinia Grapulin, Roberto Freilone, Giovannino Ciccone, Andrea Evangelista
Publikováno v:
Blood Advances
Key Points The prognosis of patients with advanced HL who achieved CMR after both 2 and 6 ABVD cycles is excellent without consolidation RT.An additional benefit of consolidation RT of sites >5 cm is likely to be small and could not be proved for thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b7535486b60d3f8dc20b8160c1abb9
https://hdl.handle.net/11368/3005933
https://hdl.handle.net/11368/3005933
Autor:
Luca Nassi, Anna Lia Molinari, Monica Tani, Pier Luigi Zinzani, Maurizio Bonfichi, Benedetta Puccini, Daniela Gioia, Alessandro Re, Alessandro Levis, Alessandro Pulsoni, Stefano Sacchi, Alessia Bari, Alessandra Tucci, Erika Meli, Chiara Pagani, Vincenzo Pavone, Raffaella Marcheselli, Umberto Vitolo, Andrea Evangelista, Barbara Botto, Armando Santoro
Publikováno v:
Ann Hematol
Annals of Hematology
Annals of Hematology
The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2fffad90d77afed15469bc6fb49f54d
https://hdl.handle.net/11380/1203344
https://hdl.handle.net/11380/1203344
Autor:
Alessandro Pulsoni, Barbara Botto, Alessandro Re, Manuel Gotti, Michele Spina, Luigi Rigacci, Andrea Evangelista, Sofia Kovalchuk, Daniela Gioia, Lara Mannelli, Manjola Dona, Luca Nassi, Benedetta Puccini, Alessandro Broccoli, Caterina Stelitano, Flavia Salvi, Armando Santoro, Chiara Pagani, Pier Luigi Zinzani, Maurizio Bonfichi
FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cb996a2f3f72571286dbb535a49edb
http://hdl.handle.net/11573/1347613
http://hdl.handle.net/11573/1347613
Autor:
Elisa Masiera, Dario Ferrero, Antonella Poloni, Paolo Danise, Rodolfo Tassara, Pellegrino Musto, Carlo Finelli, Giovanni Cametti, Bernardino Allione, Emanuela Messa, Margherita Bonferroni, Valeria Santini, Alessandro Levis, Giuseppe Saglio, Alessandro Sanna, Enrico Balleari, Daniela Gioia, Flavia Salvi, Manuela Ceccarelli, Anna Castiglione
Publikováno v:
Haematologica. 104:e4-e8
Clinical guidelines recommend the use of erythropoietin-stimulating agents (ESA) in anemic patients with lower risk myelodysplastic syndrome (MDS)[1][1]–[4][2] and two registration trials for ESA have just been completed.[5][3],[6][4] We conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f39c63ca01a89a13b777d5c81ac75d6
https://doi.org/10.3324/haematol.2017.183590
https://doi.org/10.3324/haematol.2017.183590
Autor:
Caterina Stelitano, Alessandro Levis, Antonio Castagnoli, Gian Mauro Sacchetti, Daniela Gioia, Giovannino Ciccone, Vincenzo Pavone, Umberto Vitolo, Lisa Argnani, Ercole Brusamolino, Maurizio Bonfichi, Andrea Evangelista, Flavia Salvi, Roberto Freilone, Pier Luigi Zinzani, Gianluca Gaidano, Armando Santoro, Umberto Ricardi, Francesco Zaja, Giuseppe Rossi, Chiara Rusconi, Luigi Rigacci, Monica Tani, Eugenio Borsatti, Alessandro Pulsoni, Antonella Anastasia, Alessandro Broccoli, Patrizia Pregno
Publikováno v:
Journal of Clinical Oncology. 34:1376-1385
Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dad5b2f0a8b2833740acc975be16f21b
https://doi.org/10.1200/jco.2015.63.0699
https://doi.org/10.1200/jco.2015.63.0699
Autor:
Maria E. Figueroa, Dario Ferrero, Monia Lunghi, Adelmo Terenzi, Francesco Onida, Valeria Santini, Bernardino Allione, Omar Abdel-Wahab, A. Pelizzari, Alessandro Sanna, M. Ceccarelli, Carlo Finelli, A. Levis, Emanuele Angelucci, Antonella Poloni, G. Saglio, Elisa Masiera, Daniela Gioia, G Zini, Daniela Cilloni
Publikováno v:
Leukemia
Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cad2ef5aa4bedfd3e6cb4b3bef80695
http://hdl.handle.net/10807/119501
http://hdl.handle.net/10807/119501